COMPARISON
Three Peptides, Side by Side
Same frame — peptide chemistry — different structures, different receptors, very different evidence profiles.
The short version
GHK-Cu, BPC-157, and Ipamorelin are all synthetic peptides studied for distinct purposes, but they differ dramatically in length, chemistry, mechanism, and how much human data backs them. GHK-Cu is a three-amino-acid copper complex with real topical human trial data. BPC-157 is a fifteen-amino-acid sequence with thirty years of animal data and almost no human trials. Ipamorelin is a five-amino-acid engineered synthetic with a known receptor, a failed human RCT, and no approved use. Structure drives function in each case — and the comparison below is most useful when read through that lens.
Comparison table
| Feature | GHK-Cu | BPC-157 | Ipamorelin |
|---|---|---|---|
| Chain length | 3 amino acids | 15 amino acids | 5 amino acids |
| Sequence origin | Natural (collagen fragment) | Semi-natural (gastric BPC protein) | Fully synthetic (GHRP-1 derivative) |
| Key structural feature | Cu(II) chelate via His imidazole | Triple proline (Pro-Pro-Pro) confers protease resistance | D-amino acids (D-2-Nal, D-Phe) + Aib; engineered protease resistance |
| Primary receptor / target | Dermal fibroblasts, lysyl oxidase, gene expression | VEGFR2 (angiogenesis); also FAK-paxillin, eNOS, GH receptor | GHS-R1a (ghrelin receptor) on pituitary somatotrophs |
| What it is studied for | Skin aging, collagen synthesis, wound healing, hair growth | Tissue repair (tendon, gut, muscle, nerve), angiogenesis | GH secretion, postoperative gut motility |
| Main species studied | Human (topical skin + hair RCTs), rat/in vitro | Rat (predominantly); 2 human safety reports | Rat/swine; human PK/PD; 1 human RCT |
| Evidence maturity | Controlled topical human data (small n); mechanistic and animal data; broad gene-expression claims less replicated | Three decades of animal data; three small human pilots; no rigorous large human trial | Human PK/PD characterized; Phase 2 RCT (missed endpoint); no approved indication |
| Regulatory status | Topical Copper Tripeptide-1: legal cosmetic ingredient (US, EU). Injectable/systemic: unapproved research chemical | Not approved anywhere; not eligible for 503A compounding; research chemical only | Never approved; FDA removed from 503A Category 2 list (2024); research chemical only |
| WADA status | Not currently listed on WADA Prohibited List | Prohibited (S0 non-approved substances) at all times | Prohibited (S2 peptide hormones / GH secretagogues) at all times |
| Human dosing established | No (topical formulations only; no human PK for systemic use) | No (no PK in humans) | Partially (IV PK/PD in volunteers; SC route not characterized) |
Reading the comparison
A few patterns stand out when the three are lined up:
Chemistry determines survival. GHK-Cu's copper chelate determines most of its biological activity — not just transport. BPC-157's triple proline is the structural reason it can survive acid. Ipamorelin's D-amino acids and Aib are deliberate engineering for protease resistance. In each case, the chemistry is not just description; it explains why the peptide can do what it is claimed to do.
Human evidence is uneven. GHK-Cu has the most controlled human data, but only for topical skin and hair applications. Ipamorelin has published human PK data and a controlled trial (which failed). BPC-157 has almost none — a two-person safety pilot and two other small reports. Preclinical breadth does not substitute for human trials, and none of these is an approved medicine.
WADA status matters for athletes. Two of the three — BPC-157 (S0) and Ipamorelin (S2) — are prohibited in competitive sport with established detection methods. GHK-Cu is currently not listed. Anyone in a sport subject to anti-doping control should check the current WADA Prohibited List directly before any research use.
All three are research chemicals (or, for GHK-Cu, cosmetic ingredients topically). This framing applies consistently across the desk: peer-reviewed citations, plain-English summaries, no medical advice, no doses.